-
21.发明公开바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权新化合物，其异构体，或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物
公开(公告)号：KR1020070114821A
公开(公告)日：2007-12-04
申请号：KR1020077024004
申请日：2006-03-17
Applicant: (주)아모레퍼시픽
Inventor： 서영거 , 김희두 , 박형근 , 오우택 , 이용실 , 박설린 , 유정현 , 박영호 , 신송석 , 김선영 , 김진관 , 정연수 , 이기화 , 최진규 , 임경민 , 고현주 , 모주현 , 김성일 , 배준호
IPC: C07C275/24 , C07C275/18 , A61K31/17
CPC classification number: C07C275/24 , C07C311/08 , C07C311/11 , C07C323/62 , C07D211/46 , C07D295/088 , C07D295/155 , C07D309/12 , C07F7/0818
Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a high activity in preventing or treating pain, migraine, arthralgia, neuralgia, neural diseases, neural injury, skin diseases, irritable bowel syndrome, inflammatory diseases, cardiac diseases, etc. A compound as a vanilloid receptor antagonist is a compound represented by the following formula Ia or an isomer and/or pharmaceutically acceptable salt thereof. In formula Ia, X is CR11=CR12 or C=C, wherein each of R11 and R12 independently represents H, a halogen atom, C1-C5 alkyl or phenyl; each of R1 and R2 independently represents H, carboxyl, C1-C5 alkyl, halogen, nitro, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylcarbonylamino, C1-C5 alkylsulfonylamino, phenylsulfonylamino, C1-C5 alkylthio, C1-C5 alkylsulfonyl or C1-C5 alkoxycarbonyl; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5, R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, phenyl or halogen, wherein the phenyl is non-substituted or substituted with at least one substituent selected from carboxyl, C1-C5 alkyl, halogen, nitro, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl and C1-C5 alkoxycarbonyl; R9 is C1-C5 alkylsulfonyl or C2-C5 alkenylsulfonyl; and R10 is H, with the proviso that when R3 is not H, R11 and R13 cannot represent H at the same time.
Abstract translation: 提供了一种作为香草素受体拮抗剂的化合物，用于预防或治疗疼痛，偏头痛，关节痛，神经痛，神经疾病，神经损伤，皮肤病，肠易激综合征，炎性疾病，心脏病等中的高活性。 香草酸受体拮抗剂是由下式Ia表示的化合物或其异构体和/或其药学上可接受的盐。 在式Ia中，X是CR 11 = CR 12或C = C，其中R 11和R 12各自独立地表示H，卤素原子，C 1 -C 5烷基或苯基; R1和R2各自独立地表示H，羧基，C1-C5烷基，卤素，硝基，C1-C5烷氧基，卤代（C1-C5）烷基，C1-C5烷基羰基，C1-C5烷基羰基氨基，C1-C5烷基磺酰基氨基，苯基磺酰基氨基， C1-C5烷硫基，C1-C5烷基磺酰基或C1-C5烷氧基羰基; R3是H，C1-C5烷基，C1-C5烷氧基或卤代（C1-C5）烷基; R4，R5，R6，R7和R8各自独立地表示H，羧基，C1-C5烷基，硝基，C2-C5烯基，C1-C5烷氧基，C2-C5炔基，卤代（C1-C5）烷基，C1-C5 烷基硫代，C 1 -C 5烷基磺酰基，C 1 -C 5烷基羰基，C 1 -C 5烷氧基羰基，苯基或卤素，其中苯基是未取代的或被至少一个选自羧基，C 1 -C 5烷基，卤素，硝基， C5链烯基，C1-C5烷氧基，卤代（C1-C5）烷基，C1-C5烷基羰基，C1-C5烷硫基，C1-C5烷基磺酰基和C1-C5烷氧基羰基; R9为C1-C5烷基磺酰基或C2-C5链烯基磺酰基; R 10为H，条件是当R3不为H时，R11和R13不能同时表示H。
-
公开(公告)号：KR101729140B1
公开(公告)日：2017-04-26
申请号：KR1020100085038
申请日：2010-08-31
Applicant: (주)아모레퍼시픽
IPC: C08K5/20 , C08L33/00 , C08J3/12 , A61K31/194
Abstract: 본발명은분지쇄아미노산및 카르복실기를포함하는고분자화합물을포함하는조성물을개시한다. 상기조성물은아미노산의쓴 맛또는냄새가차폐되어복용하기편리하다. 또한본 발명은분지쇄아미노산과카르복실기를포함하는고분자화합물을혼합하는단계를포함하는분지쇄아미노산의쓴 맛또는냄새차폐방법을개시한다.
Abstract translation: 本发明公开了包含含有支链氨基酸和羧基的聚合物的组合物。 该组合物很容易摄入，因为它可以防止苦味或氨基酸的味道。 本发明还公开了支链氨基酸的苦味或气味遮蔽方法，其包括混合包含支链氨基酸和羧基的聚合物化合物的步骤。
-
公开(公告)号：KR1020140140847A
公开(公告)日：2014-12-10
申请号：KR1020130061761
申请日：2013-05-30
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/365 , A61K8/022 , A61K8/06 , A61K8/19 , A61K2800/222 , A61K2800/882 , A61Q19/00 , A61Q19/007 , A61Q19/02
Abstract: 본 발명의 일측면은 수용성 활택제를 함유하는 발포형 정제 및 이와 함께 사용할 수 있는 탄산수 화장료 조성물에 관한 것이다. 본 발명은 일측면에서, 결정형 알파하이드록시산 및 수용성 활택제를 포함하는 발포형 정제와 이를 화장료 조성물 내에서 부유하지 않고 빠르게 탄산을 발포할 수 있도록 하여 시각적 효과와 더불어 탄산의 효능을 극대화함으로써 피부 미백, 브라이트닝, 보습 효과가 있고, 모공을 개선하는 화장수를 이용한 화장료 조성물에 대한 것이다.
Abstract translation: 本发明的一个方面涉及包含可溶性润滑剂的泡腾片剂和可与同一片剂一起使用的起泡水化妆品组合物。 根据本发明的方面，本发明涉及：包含结晶的α-羟基酸和可溶性润滑剂的泡腾片; 以及防止泡腾片在其中漂移的化妆品组合物，并且使泡腾片快速产生碳酸盐气泡以提供视觉效果并使碳酸盐的效果最大化。 因此，化妆品组合物具有使皮肤美白，增亮皮肤，保湿皮肤，改善毛孔状态的效果。
-
-
-
Patent Agency Ranking
公开(公告)号：KR1020110123602A
公开(公告)日：2011-11-15
申请号：KR1020100043161
申请日：2010-05-07
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/06 , A61K8/042 , A61K2800/412 , A61L27/52 , A61L27/54 , A61L2430/24 , A61L2430/34 , A61Q19/00
Abstract: PURPOSE: A method for preparing water-insoluble gel composition is provided to ensure excellent physical property such as density and strength. CONSTITUTION: A method for preparing water-insoluble gel composition comprises: a step of adding water, dispersion agent, soluble polymers, pH adjusting agent, and crosslinking agent to prepare a composition; and a step of removing the dispersion agent from the composition. The water soluble polymer contains carboxyl group(-COOH), carboxylate and hydroxy group(-OH) or hydroxylate. The dispersion agent is acetone, tetrahydrofuran, methanol, ethanol, propanol, isopropanol, butanol, pantanol, or hexanol.
Abstract translation: 目的：提供一种制备水不溶性凝胶组合物的方法，以确保物理性能如密度和强度等优异性能。 构成：制备水不溶性凝胶组合物的方法包括：加入水，分散剂，可溶性聚合物，pH调节剂和交联剂以制备组合物的步骤; 以及从组合物中除去分散剂的步骤。 水溶性聚合物含有羧基（-COOH），羧酸酯和羟基（-OH）或羟基化物。 分散剂为丙酮，四氢呋喃，甲醇，乙醇，丙醇，异丙醇，丁醇，四氢呋喃或己醇。
-
公开(公告)号：KR1020110075011A
公开(公告)日：2011-07-05
申请号：KR1020117010529
申请日：2009-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/5047 , A61K9/5026 , A61K9/5042 , A61K9/16 , A61K47/50
Abstract: PURPOSE: A sustained release fine particle containing a matrix containing pharmaceutically active ingredients and a sustained release layer is provided to ensure excellent elution effect. CONSTITUTION: A sustained release fine particle comprises: a matrix containing pharmacologically active ingredients; and a sustained release layer containing a sustained release membrane forming material on the matrix. The sustained release membrane forming material is a water insoluble polymer, enteric polymer, soluble polymer, or mixture thereof. The insoluble polymer is ethyl cellulose, cellulose ether, acrylic acid ethyl-methacrylic acid methyl-methacrylic acid trimethyl ammonium ethyl chloride copolymer, polyvinyl acetate, and acrylic acid ethyl-methacrylic acid methyl copolymer or dispersion solution thereof. The soluble polymer is hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrolidone, or polyvinyl alcohol. The matrix further contains an excipient or binder.
Abstract translation: 目的：提供含有含有药物活性成分和持续释放层的基质的缓释微粒，以确保优异的洗脱效果。 构成：缓释微粒包括：含有药理活性成分的基质; 以及在基质上含有缓释膜形成材料的持续释放层。 缓释膜形成材料是水不溶性聚合物，肠溶聚合物，可溶性聚合物或其混合物。 不溶性聚合物是乙基纤维素，纤维素醚，丙烯酸乙基 - 甲基丙烯酸甲基 - 甲基丙烯酸三甲基铵乙基氯共聚物，聚乙酸乙烯酯和丙烯酸乙基 - 甲基丙烯酸甲基共聚物或其分散溶液。 可溶性聚合物是羟丙基纤维素，羟丙基甲基纤维素，聚乙烯吡咯烷酮或聚乙烯醇。 基质还含有赋形剂或粘合剂。
-
公开(公告)号：KR1020100052253A
公开(公告)日：2010-05-19
申请号：KR1020080111190
申请日：2008-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/41 , A61K9/0053 , A61K9/2095
Abstract: PURPOSE: A method for manufacturing a solid oral formulation containing valsartan is provided to effectively obtain an oral formulation having excellent disintegration force and dissolution rate. CONSTITUTION: A method for manufacturing a solid oral formulation containing valsartan comprises: a step of contacting valsartan and pharmaceutically acceptable additive with binding solution; a step of drying resultant; a step of granulating the dried resultant; and a step of mixing the granule with disintegrant and lubricant. The binding solution is water, or mixture of water and ethanol. The disintegrant is crospovidone.
Abstract translation: 目的：提供一种制备含缬沙坦固体口服制剂的方法，以有效获得具有优异的崩解力和溶出率的口服制剂。 构成：制备含缬沙坦的固体口服制剂的方法包括：将缬沙坦和药学上可接受的添加剂与结合溶液接触的步骤; 干燥结果的步骤; 造粒干燥物的步骤; 以及将颗粒与崩解剂和润滑剂混合的步骤。 结合溶液是水，或水和乙醇的混合物。 崩解剂是交聚维酮。
-
公开(公告)号：KR1020090027734A
公开(公告)日：2009-03-17
申请号：KR1020097001187
申请日：2007-07-26
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/5123 , A61K9/0019 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/5161 , A61K9/5192
Abstract: A manufacturing method of powder including nano particles of insoluble drug is provided to maintain stability in case that insoluble drug is re-dispersed at aqueous solution, to be no side effect by impurity and to improve bio-availability. A manufacturing method of powder including nano particles of insoluble drug comprises steps of: adding particles of insoluble drug which is active component, a surface passivating agent and additional dispersion secondary particle in aqueous solution including dispersion secondary particle to aturation concentration; mixing, shattering and homogenizing the obtained dispersed solution; and centrifuging or filtering the homogenized dispersed solution and drying it and obtaining the powder from the dispersed solution.
Abstract translation: 提供包含不溶性药物的纳米颗粒的粉末的制造方法，以在不溶性药物在水溶液中再分散的情况下保持稳定性，不会由杂质产生副作用并提高生物利用度。 包含不溶性药物纳米颗粒的粉末的制造方法包括以下步骤：在包含分散二次颗粒的水溶液中加入作为活性成分的不溶性药物颗粒，表面钝化剂和附加的分散二次颗粒以使其成为浓度; 混合，粉碎和均化所得分散溶液; 离心或过滤均匀分散的溶液并干燥并从分散溶液中获得粉末。
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.026 seconds)
